FORT LAUDERDALE, Florida

Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the upcoming presentation of two abstracts supporting the ongoing clinical development of its OncAlert™ Oral Cancer Product Line at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place in Philadelphia, PA on April 18-22, 2015.

Details for the two poster presentations are as follows:

Wednesday, Apr 22, 2015 8:00 AM – 12:00 PM, location 40
Poster Session: LBPO.PR01. Late-Breaking Research: Prevention Research

Abstract # LB-272 (Poster 10), “Effect of smoking cessation on soluble CD44 levels in head and neck cancer,” Authors: Faisal F. Alotaibi, Turki M. Almuhaimid, Erika Reategui, Isildinha M. Reis, Claudia Gordon, Rohit Mathur, William Goodwin, Elizabeth J. Franzmann, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

Abstract # LB-269 (Poster 7), “Nutritional effect on CD44 in head and neck cancer,” Authors: Turki M. Almuhaimid, Erika P. Reategui, Faisal Alotaibi, Gordon Claudia, Isildinha M. Reis, W. Jarrad Goodwin and Elizabeth J. Franzmann, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

The meeting abstracts can be viewed online through the AACR website at www.aacr.org.

About the OncAlert Oral Cancer Product Line
Vigilant Biosciences’ initial products, the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) and the OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”), are the first and only technologies that measure soluble CD44 and total protein levels – protein markers clinically shown to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus). The OncAlert LAB Test is CE Marked. The OncAlert RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer product line is not yet available for sale in the U.S.

About Oral Cancer
According to the Oral Cancer Foundation, there are over 640,000 new cases of oral cancer each year worldwide. In the U.S., close to 48,250 individuals will be diagnosed with oral or pharyngeal cancer this year, with 9,575 deaths from the disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Vigilant’s OncAlert Oral Cancer product line includes rapid and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert Oral Cancer product line is not yet available for sale in the U.S. For more information, visit www.vigilantbiosciences.com.